Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT

Allogenic hematopoietic stem cell transplantation (allo‐HCT) is the standard treatment for acute myeloid leukemia (AML) in non‐complete remission (non‐CR); however, the prognosis is inconsistent. This study aimed to develop and validate nomograms and a web application to predict the overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirabayashi, Shigeki, Uozumi, Ryuji, Kondo, Tadakazu, Arai, Yasuyuki, Kawata, Takahito, Uchida, Naoyuki, Marumo, Atsushi, Ikegame, Kazuhiro, Fukuda, Takahiro, Eto, Tetsuya, Tanaka, Masatsugu, Wake, Atsushi, Kanda, Junya, Kimura, Takafumi, Tabuchi, Ken, Ichinohe, Tatsuo, Atsuta, Yoshiko, Yanada, Masamitsu, Yano, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267144/
https://www.ncbi.nlm.nih.gov/pubmed/34132501
http://dx.doi.org/10.1002/cam4.3920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267144/
https://www.ncbi.nlm.nih.gov/pubmed/34132501
http://dx.doi.org/10.1002/cam4.3920

Ejemplares similares